52
Total investments
16
Early stage
15
Mid stage
9
Late stage
6y
Years active
Portfolio
50 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2026
BranchLab is the AI platform for biopharma commercialization. Biopharma companies and their marketing agencies in-house BranchLab’s platform to model high-value patient and provider populations, activate omnichannel, and measure real-world outcomes without using personal health data.
The BranchLab platform is designed to streamline how therapies are brought to market in the AI era
Board Member & Lead Investor
Jul 2025
ALIGNMT AI enables healthcare organizations to confidently deploy advanced AI solutions by proactively addressing the core risks that hinder adoption: patient safety, data security, billing accuracy, and regulatory compliance. By operationalizing AI governance, we help health systems, payers, and life sciences companies unlock the full value of AI—safely, transparently, and at enterprise scale.
Board Member & Lead Investor
May 2025
WearLinq is a provider of digital healthcare solutions with a focus on ambulatory electrocardiogram (ECG) monitoring. The unique WearLinq system is designed to elevate the standard of remote cardiac monitoring by the enhanced detection of heart rhythm disorders and effectively reducing overall healthcare costs.
The Wearlinq platform (or system) includes the first FDA cleared 6-lead cardiac monitor with multidimensional views of the heart for electrocardiogram (ECG) studies.
Wearlinq is an Independent Diagnostic Testing Facility (“IDTF”) with clinical operations in Rockville, MD.
Board Observer & Lead Investor
May 2025
Meet Chromie, the future of hospital workforce automation. As seen in Forbes 30 Under 30, Chromie Health is revolutionizing hospital staffing and administration with AI-powered automation. Our platform seamlessly integrates with systems like ADT and Epic, replacing outdated manual processes with real-time, data-driven workforce management. Chromie generates optimal schedules in a single click, reducing nurse scheduling time by 8 hours per week and cutting annual staffing costs by $320K per unit.
Chromie isn’t just another scheduling tool; it’s the first of many AI-driven solutions designed to transform hospital operations. By enhancing workforce efficiency, improving patient outcomes, and automating complex workflows, Chromie empowers hospitals to stay ahead of the growing demand for smarter, scalable solutions.
With seamless 6-8 week integration, HIPAA-compliant AI that works with existing tech stacks, and proven success, Chromie Health is leading the charge in redefining healthcare workforce management, saving hospitals time, money, and lives.
Board Member & Investor
Apr 2025
Stealth AI Startup is an independent initiative focused on founders building AI companies before public launch.
We explore the earliest stages of building an AI startup—from testing an idea and finding collaborators to assembling a team and preparing to launch.
Our focus:
• Founder experiences and lessons from building in stealth
• Emerging AI technologies and startup trends
• Perspectives from founders, researchers, engineers and investors
• Practical learning for the journey from idea to launch
We believe founders can exchange knowledge and build meaningful professional connections while keeping their products and plans confidential.
This is the official LinkedIn Page of the Stealth AI Startup initiative. It represents our initiative, rather than the separate companies built by founders who follow it. Following or engaging with this page does not, by itself, establish employment, partnership or endorsement.
Follow us for perspectives on building AI companies and updates from our initiative.
Visit us at https://www.stealthaistartup.online/
Board Observer & Investor
Apr 2025
Developing the next generation of life-saving regenerative medicines with the worlds most advanced ML cell imaging platform.
Board Observer & Investor
Mar 2025
A network for entrepreneurs building in stealth.
Submit your information here so investors can find you:
harmonic.ai/get-discovered
Board Observer & Investor
Jan 2025
More than half of all clinical trials fail due to safety issues. Discovering drugs that show therapeutic potential is difficult, time-consuming, and expensive. But of those found, it is harder still to find those drugs which do not also have severe side effects and can pass through clinical trials.
Most of these drugs are shelved and never reach patients. Safety issues are tough to fix without weakening the therapeutic effect, involving a mix of chemistry, biology, and knowledge of how humans will respond.
Our proprietary AI model, SAFEPATH©, applies deep learning to our combined bioinformatics and cheminformatics datasets to solve drug safety issues. SAFEPATH© utilises the latest deep learning approaches to identify the mechanism of toxicity, predict its effects on the human body, and balance that with therapeutic effectiveness.
We are building at speed a robust pipeline of matured assets. We look at historically failed clinical trials to identify the most promising targets as well as internal projects that were abandoned. By focusing on safety problems that occur in Preclinical, Phase 1, or Phase 2 trials, we are able to identify the most promising drugs therapeutically, turn them around quickly, and get them to patients faster than starting drug discovery from scratch.
Our mission is to bring more treatments to patients, faster. Thousands of life-changing drugs fall at the last hurdle and never reach patients. We’re here to change that.
Board Member & Investor
Dec 2024
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data.
Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
Show all 50 investments ↓
Experience · 56 entries
All (56)
Investments (52)
Board (14)
2026
Investor
Apr 2026
BranchLab is the AI platform for biopharma commercialization. Biopharma companies and their marketing agencies in-house BranchLab’s platform to model high-value patient and provider populations, activate omnichannel, and measure real-world outcomes without using personal health data.
The BranchLab platform is designed to streamline how therapies are brought to market in the AI era
2025
Board Member & Lead Investor
Jul 2025
ALIGNMT AI enables healthcare organizations to confidently deploy advanced AI solutions by proactively addressing the core risks that hinder adoption: patient safety, data security, billing accuracy, and regulatory compliance. By operationalizing AI governance, we help health systems, payers, and life sciences companies unlock the full value of AI—safely, transparently, and at enterprise scale.
Show all 56 entries ↓
Investment activity
2020–2026 · 52 investments
Recent (last 2 years)Earlier
